SUGAR secondary outcomes

Release of the PMI-0.4 SUGAR software and standard operating procedures used to generate renal and cardiac perfusion outcomes in the SUGAR trial. SUGAR is a comprehensive clinical trial to interrogate in detail the effects of empagliflozin on specific pathways (inclusive of cardiac and renal effects) in patients with type 2 diabetes (or pre-diabetes) and heart failure (https://clinicaltrials.gov/ct2/show/NCT03485092).